Funded Biotechnology Startups in Lund
Lund’s most recent disclosed biotechnology rounds are anchored by Asgard Therapeutics’ $33M on 2024-03-14, which dwarfs the next-largest disclosed amounts…
Lund’s most recent disclosed biotechnology rounds are anchored by Asgard Therapeutics’ $33M on 2024-03-14, which dwarfs the next-largest disclosed amounts in this view ($4M Cellevate on 2023-10-10 and $3M Cantargia on 2025-06-17, with most other disclosed rounds at $2M or below). A second standout is the stage pattern: 8 of 12 entries list “Series Unknown” (Alligator Bioscience 2026-05-05 $2M; SynAct Pharma 2025-07-15 $2M; Qlucore 2025-06-24 $580K; Cantargia 2025-06-17 $3M; Clinical Laserthermia Systems 2024-11-26 $2M; Carbiotix 2024-02-01 $1M; Gedea Biotech 2023-05-24 $1M; BioInvent 2023-04-26 $3M), while the remaining 4 include Pre-Seed (Emulsi Biotech 2026-06-16 $740K), Seed (Cellevate 2023-10-10 $4M), and one blank stage label (Asgard Therapeutics 2024-03-14 $33M). Temporally, the 12-row slice runs from 2023-04-14 (Hamlet Pharma) to 2026-06-16 (Emulsi Biotech), and the city field stays consistent as “Lund, Skane Lan, Sweden” across all rows.
Most recent rounds
12 shownRelated listings
Frequently asked
What’s the largest disclosed biotech round in the Lund list, and how does it compare with the rest of the disclosed amounts?
Asgard Therapeutics’ $33M round on 2024-03-14 is an outlier; the next-largest disclosed amounts in this view are much smaller at $4M (Cellevate, 2023-10-10) and $3M (Cantargia, 2025-06-17). Most other disclosed rounds cluster at $2M or below (e.g., Alligator Bioscience $2M on 2026-05-05; Clinical Laserthermia Systems $2M on 2024-11-26; multiple entries at $1M).
Are there date clusters among the most recent rounds shown?
Yes. Four disclosed rounds fall between 2025-06-17 and 2025-07-15 (Cantargia $3M on 2025-06-17; Qlucore $580K on 2025-06-24; SynAct Pharma $2M on 2025-07-15; plus the 2025-06-24–2025-07-15 window is populated by two entries). Another visible block is early 2024, spanning 2024-02-01 (Carbiotix $1M) through 2024-11-26 (Clinical Laserthermia Systems $2M) with multiple entries in between (including Asgard Therapeutics at $33M on 2024-03-14).
How dominant is “Series Unknown” among these Lund biotech deals?
8 of 12 entries use “Series Unknown” (e.g., Alligator Bioscience $2M on 2026-05-05; SynAct Pharma $2M on 2025-07-15; Cantargia $3M on 2025-06-17; Clinical Laserthermia Systems $2M on 2024-11-26; BioInvent $3M on 2023-04-26). The remaining 4 cover different labels: Emulsi Biotech is Pre-Seed ($740K on 2026-06-16), Cellevate is Seed ($4M on 2023-10-10), Asgard Therapeutics has a blank stage label ($33M on 2024-03-14), and the rest are explicitly “Series Unknown.”
What stage mix appears when you look only at the non-“Series Unknown” entries?
Beyond “Series Unknown,” the labeled stages are concentrated in Pre-Seed and Seed. Emulsi Biotech is Pre-Seed ($740K, 2026-06-16) and Cellevate is Seed ($4M, 2023-10-10), while Asgard Therapeutics is the only entry with an empty stage label ($33M, 2024-03-14).
Any notable low-end outliers worth attention in the disclosed amounts?
On the low end, Qlucore’s $580K on 2025-06-24 is the smallest disclosed amount in this view, below other sub-$1M figures like none appear in the list (the next-lowest disclosed is Hamlet Pharma at $330K on 2023-04-14, which is actually even lower than Qlucore). Relative to the $33M outlier (Asgard Therapeutics), the smallest disclosed rounds (Hamlet Pharma $330K on 2023-04-14 and Qlucore $580K) sit far below the rest of the distribution.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.